See more : Tera Light Ltd (TRLT.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Newbury Pharmaceuticals AB (publ) (NEWBRY.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Newbury Pharmaceuticals AB (publ), a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- T-Bull S.A. (TBL.WA) Income Statement Analysis – Financial Results
- Samsung Fire & Marine Insurance Co., Ltd. (000810.KS) Income Statement Analysis – Financial Results
- Science in Sport plc (SIS.L) Income Statement Analysis – Financial Results
- NEO Battery Materials Ltd. (NBM.V) Income Statement Analysis – Financial Results
- NH Investment & Securities Co., Ltd. (005940.KS) Income Statement Analysis – Financial Results
Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.newburypharma.com
About Newbury Pharmaceuticals AB (publ)
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden, and Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. The company was incorporated in 2020 and is based in Lund, Sweden.
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 36.83M | 10.27M | 5.52M | 2.83M |
| Cost of Revenue | 20.80M | 6.32M | 3.95M | 2.37M |
| Gross Profit | 16.03M | 3.95M | 1.56M | 460.00K |
| Gross Profit Ratio | 43.53% | 38.46% | 28.35% | 16.26% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 2.81M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 2.81M |
| Other Expenses | 30.11M | 21.17M | 0.00 | 0.00 |
| Operating Expenses | 30.11M | 21.17M | 13.94M | 6.08M |
| Cost & Expenses | 50.91M | 27.48M | 17.89M | 8.45M |
| Interest Income | 0.00 | 156.00K | 0.00 | 99.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 35.00K |
| Depreciation & Amortization | 1.74M | 1.26M | 1.01M | 608.00K |
| EBITDA | -12.34M | -18.33M | -13.66M | -4.91M |
| EBITDA Ratio | -33.51% | -177.05% | -247.66% | -173.70% |
| Operating Income | -14.08M | -19.59M | -14.67M | -5.62M |
| Operating Income Ratio | -38.23% | -190.79% | -265.90% | -198.69% |
| Total Other Income/Expenses | -1.33M | 156.00K | 0.00 | 64.00K |
| Income Before Tax | -15.41M | -19.43M | -14.67M | -5.56M |
| Income Before Tax Ratio | -41.84% | -189.28% | -265.90% | -196.43% |
| Income Tax Expense | -4.00K | 156.00K | 0.00 | 99.00K |
| Net Income | -15.41M | -19.43M | -14.67M | -5.56M |
| Net Income Ratio | -41.83% | -189.28% | -265.90% | -196.43% |
| EPS | -0.72 | -1.00 | -0.75 | -0.35 |
| EPS Diluted | -0.72 | -1.00 | -0.75 | -0.35 |
| Weighted Avg Shares Out | 21.41M | 19.52M | 19.52M | 15.68M |
| Weighted Avg Shares Out (Dil) | 21.41M | 19.52M | 19.52M | 15.68M |
Source: https://incomestatements.info
Category: Stock Reports